Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Edwards Lifesciences wants a federal judge to invalidate a pair of patents covering nerve stimulation sensing technology owned by arch-rival Medtronic. Edwards Lifesciences (NYSE:EW) wants a federal judge to rule that a pair of patents owned by arch-rival Medtronic (NYSE:MDT) are invalid because they aren’t specific enough. The patents – the so-called ‘741 patent for a “Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure” and the ‘829 patent for a “Method and system for nerve stimulation prior to and during a medical procedure – cover nerve stimulation technology.
Help employers find you! Check out all the jobs and post your resume.
